Meg Dodge

Bio:

Meg Dodge is a seasoned biotech executive with over 15 years of experience spanning capital markets, strategic communications, and rare disease advocacy. She currently serves as Senior Vice President of Investor Relations and Corporate Communications at Rocket Pharmaceuticals, a clinical-stage gene therapy company focused on developing transformative treatments for rare and devastating pediatric diseases.

At Rocket, Meg leads the company’s investor relations strategy and all external communications, serving as a trusted advisor to executive leadership and the Board. She oversees financial disclosure planning, market and analyst engagement, earnings communications, and patient-focused campaigns, ensuring that the company’s messaging is clear, credible, and aligned with its mission. Her work has helped establish Rocket’s reputation as a leader in gene therapy, including during periods of high visibility and scrutiny such as clinical holds, regulatory milestones, and cross-stakeholder engagement efforts.

Previously, Meg led investor relations and communications at Krystal Biotech during a pivotal phase of growth, supporting the commercial launch of the first redosing gene therapy for a rare skin disease and managing visibility across oncology pipeline expansion, FDA interactions, and community-based advocacy. She developed and executed fully integrated communications strategies that reached institutional investors, policymakers, patients, and media alike.

Prior to transitioning into biotech, Meg held senior roles in strategy and business development for private healthcare companies and began her career at Goldman Sachs in equity research and investment banking. This foundation gives her a unique ability to translate complex science and regulatory nuance into language that resonates across Wall Street, patient communities, and Capitol Hill.

Meg is known for building high-impact, cross-functional communications platforms that align internal teams and external stakeholders around a unified vision, particularly in fast-moving, high-stakes environments. She is a passionate advocate for science-driven storytelling, policy modernization, and public trust in gene therapy innovation.

She holds a J.D. from Syracuse University College of Law, an LL.M. from NYU School of Law, and a B.A. from Colby College.